FDA Date: 6/17/09
Maxipime (cefepime) FDA Drug Safety Communication
Follow-Up to Cefepime (marketed as Maxipime) Safety Review: An Update
FDA has finished its analysis of a possible risk of higher death with cefepime, an antibiotic, following publication of a study that suggested a higher rate of death in patients treated with this drug compared to patients treated with similar drugs. FDA has determined that the data do not indicate a higher rate of death in cefepime-treated patients. Cefepime remains an appropriate therapy for its approved indications.